The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.
The invention consists of new bi-functional protein inhibitors (“BPIs”) for treatment and diagnostics of autoimmune diseases such as MS and experimental autoimmune encephalomyelitis. The novel BPIs are capable of modulating the immune response towards a TH2 response.
Immuno-oncology represents the new wave of personalized medicine. Scientists at the University of Kansas have developed an innovative approach to activate intracellular signaling pathways that enhance T cell activation, expansion, and differentiation.
Small molecule adjuvants that act as vaccine adjuvants by specifically binding to Toll-Like Receptor-8 (TLR8).
The invention provides novel compounds (adjuvants) that can be used as agonists for Toll-Like Receptor 7 (TLR7). By specifically targeting TLR7, these adjuvants elicit a type 1 interferon response which is essential in the development of antiviral responses.